Christopher L Pathoulas
Overview
Explore the profile of Christopher L Pathoulas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franco-Acevedo A, Pathoulas C, Murphy P, Valenzuela N
J Immunol
. 2023 Oct;
211(9):1276-1285.
PMID: 37844279
Ab-mediated rejection of organ transplants remains a stubborn, frequent problem affecting patient quality of life, graft function, and grant survival, and for which few efficacious therapies currently exist. Although the...
2.
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
Ray U, Thirusangu P, Jin L, Xiao Y, Pathoulas C, Staub J, et al.
Oncogene
. 2023 Aug;
42(37):2725-2736.
PMID: 37550562
PG545 (Pixatimod) is a highly sulfated small molecule known for its ability to inhibit heparanase and disrupt signaling mediated by heparan-binding-growth factors (HB-GF). Previous studies indicated that PG545 inhibits growth...
3.
Ray U, Pathoulas C, Thirusangu P, Purcell J, Kannan N, Shridhar V
Cancer Res
. 2022 Mar;
82(9):1675-1681.
PMID: 35260879
Abundant fibrotic stroma is a typical feature of most solid tumors, and stromal activation promotes oncogenesis, therapy resistance, and metastatic dissemination of cancer cells. Therefore, targeting the tumor stroma in...
4.
Oien D, Ray U, Pathoulas C, Jin L, Thirusangu P, Jung D, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572872
A considerable subset of gynecologic cancer patients experience disease recurrence or acquired resistance, which contributes to high mortality rates in ovarian cancer (OC). Our prior studies showed that quinacrine (QC),...
5.
Thirusangu P, Pathoulas C, Ray U, Xiao Y, Staub J, Jin L, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33919392
We previously reported that the antimalarial compound quinacrine (QC) induces autophagy in ovarian cancer cells. In the current study, we uncovered that QC significantly upregulates cathepsin L (CTSL) but not...
6.
Oien D, Pathoulas C, Ray U, Thirusangu P, Kalogera E, Shridhar V
Semin Cancer Biol
. 2019 Sep;
68:21-30.
PMID: 31562955
Quinacrine, also known as mepacrine, has originally been used as an antimalarial drug for close to a century, but was recently rediscovered as an anticancer agent. The mechanisms of anticancer...